NCT04091048已完成不适用
Optimize PRO Transcatheter Aortic Valve Replacement Post Market Study
Medtronic Cardiovascular97 个研究点 分布在 7 个国家目标入组 1,127 人开始时间: 2019年9月16日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,127
- 试验地点
- 97
- 主要终点
- All-cause Mortality or All-stroke
研究概览
简要总结
The purpose of this study is to collect clinical evidence on valve performance and procedural outcomes associated with an "optimized" TAVR care pathway and post-TAVR conduction disturbance pathway while using the Evolut™ PRO and Evolut™ PRO+ devices.
The purpose of the addendum is to collect post-market clinical evidence on valve performance and procedural outcomes associated with the Evolut FX Device.
详细描述
This is a post market, multi-center (sites in US/CAN/EMEA/ANZ), prospective, non-randomized study.
The addendum is a post market, multi-center (sites in US only), prospective, non-randomized study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acceptable candidate for treatment with the Evolut™ PRO or Evolut™ PRO+ system (FX system for the addendum where applicable) in accordance with the Instructions for Use and local regulations;
- •Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by New York Heart Association (NYHA) Functional Class II or greater;
- •Subject and the treating physician agree that the subject will return for all required post procedure follow-up visits;
- •Anatomically suitable for transfemoral TAVR with the Medtronic TAVR system;
- •Subject meets the legal minimum age to provide Informed Consent based on local regulatory requirements.
排除标准
- •Contraindicated for treatment with the Evolut™ PRO or Evolut™ PRO+ or FX system (where applicable) in accordance with the Instructions for Use
- •Anatomically not suitable for the Evolut™ PRO or Evolut™ PRO+ or FX system (where applicable);
- •Previous aortic valve replacement
- •Reduced ventricular function with left ventricular ejection fraction (LVEF) <35% as measured by resting echocardiogram;
- •Frailty assessments identify:
- •Subject is <80 years of age and three or more of the following apply; OR subject is > 80 years of age and two or more of the following apply
- •Wheelchair bound
- •Resides in an institutional care facility (e.g. nursing home, skilled care center)
- •Body Mass Index <20kg/m2
- •Grip strength <16kg
- •Katz Index score ≤4
- •Albumin <3.5 g/dL
- •Bicuspid valve verified;
- •Aortic root angulation (angle between plane of aortic valve annulus and horizontal plane/vertebrae) > 70°.
- •Implanted with pacemaker or ICD;
- •Prohibitive left ventricular outflow tract calcification;
- •Estimated life expectancy of less than 12 months due to associated non- cardiac co-morbid conditions;
- •Other medical, social, or psychological conditions that in the opinion of the Investigator precludes the subject from appropriate consent, adherence to the protocol required follow-up exams;
- •Currently participating in an investigational drug or another device trial (excluding registries);
- •Need for emergency surgery for any reason.
- •Subject is less than legal age of consent, legally incompetent, or otherwise vulnerable*.
- •Notes: Vulnerable subjects include individuals whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate. EXAMPLE Individuals with lack of or loss of autonomy due to immaturity or through mental disability, persons in nursing homes, children, impoverished persons, subjects in emergency situations, ethnic minority groups, homeless persons, nomads, refugees, and those incapable of giving informed consent. Other vulnerable subjects include, for example, members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the sponsor, members of the armed forces, and persons kept in detention.
研究组 & 干预措施
Primary Cohort
干预措施: Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum) (Device)
结局指标
主要结局
All-cause Mortality or All-stroke
时间窗: 30 days post procedure
All-cause mortality or all-stroke at 30 days.
次要结局
- Aortic Regurgitation (AR)(Through discharge up to 7 days post index procedure.)
- Pacemaker Implantation or Worsening Conduction Disturbance(30 days)
- Length of Stay(Through discharge up to 7 days post index procedure.)
- Depth of Implant (Evolut FX Only)(30 days)
- Canting (Evolut FX Addendum Only)(30 Days)
研究者
研究点 (97)
Loading locations...
相似试验
招募中
不适用
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuREAortic StenosisNCT06777368Medtronic Cardiovascular225
进行中（未招募）
不适用
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).Severe Aortic StenosisNCT01586910Medtronic Cardiovascular1,746
Unknown
不适用
The Asian Pacific TAVR Multicenter RegistryAortic Valve StenosisNCT02195102Michael Kang-Yin Lee, MD2,000
进行中（未招募）
不适用
Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)Aortic Valve StenosisNCT02661451Cardiovascular Research Foundation, New York178
已完成
不适用
The Bicuspid Aortic Stenosis Following Transcatheter Aortic Valve Replacement RegistryAortic Valve StenosisCardiovascular DiseasesHeart Valve DiseasesBicuspidNCT02394184Seung-Jung Park102